Single high dose of liposomal amphotericin B + L-AmB standard dose
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Disseminated Histoplasma Capsulatum Infection
Conditions
Disseminated Histoplasma Capsulatum Infection, AIDS and Infections, Immunosuppression, Fungal Infection
Trial Timeline
Jan 16, 2025 → Nov 28, 2026
NCT ID
NCT05814432About Single high dose of liposomal amphotericin B + L-AmB standard dose
Single high dose of liposomal amphotericin B + L-AmB standard dose is a phase 3 stage product being developed by Gilead Sciences for Disseminated Histoplasma Capsulatum Infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05814432. Target conditions include Disseminated Histoplasma Capsulatum Infection, AIDS and Infections, Immunosuppression.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05814432 | Phase 3 | Recruiting |
Competing Products
5 competing products in Disseminated Histoplasma Capsulatum Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KW-3357 | Kyowa Kirin | Phase 3 | 77 |
| KW-3357 | Kyowa Kirin | Phase 3 | 77 |
| KW-3357 + Plasma-derived antithrombin | Kyowa Kirin | Phase 3 | 77 |
| BAY 3389934 + Matching Placebo / Diluent | Bayer | Phase 1 | 30 |
| Flucytosine and fluconazole + Fluconazole | Bausch Health | Phase 2 | 47 |